Compassionate Use of Lorlatinib:PF-06463922 for Male Patient

Overview

About this study

Lorlatinib:PF-06463922 being provided to a single patient on a compassionate basis because of lung cancer characterized by genetic abnormalities in anaplastic lymphoma kinase (ALK).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Please contact the study team to discuss whether or not you are eligible to participate in a study.

Inclusion Criteria:

  • Progressive, metastatic ALK-mutant lung cancer

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Aaron Mansfield, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20304539

Mayo Clinic Footer